TY - JOUR T1 - Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer <em>In Vivo</em> JF - Anticancer Research JO - Anticancer Res SP - 2867 LP - 2874 DO - 10.21873/anticanres.15068 VL - 41 IS - 6 AU - YU-CHANG LIU AU - FEI-TING HSU AU - JING-GUNG CHUNG AU - MAO-CHI WENG AU - CHIEN-YI TING AU - CHIA-JUNG TSAI AU - ALEXANDER LAN AU - JENG-YUAN WU AU - CHARLES CHUNG-WEI LIN AU - SONG-SHEI LIN Y1 - 2021/06/01 UR - http://ar.iiarjournals.org/content/41/6/2867.abstract N2 - Background/Aim: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with poor prognosis. Lenvatinib is a multi-kinase inhibitor that has the potential to suppress tumor progression. Our previous study suggested that lenvatinib induces cytotoxicity and apoptosis in CL-1-5-F4 cells in vitro. However, whether lenvatinib suppresses NSCLC progression in vivo remains unclear. Materials and Methods: Tumor growth inhibition and normal tissue toxicity evaluation following lenvatinib treatment were performed on CL-1-5-F4-bearing mice. Results: Tumor growth calculated by caliper and living cell intensity decreased by lenvatinib treatment as analysed by bioluminescence imaging. Phosphorylation of AKT, NF-κB, and NF-κB downstream proteins involved in tumor progression were reduced by lenvatinib in the tumor tissue. No pathological changes were found in the liver, kidney, and spleen after lenvatinib treatment. Conclusion: Induction of apoptosis and suppression of AKT/NF-κB were associated with lenvatinib-induced inhibition of the progression of NSCLC in vivo. ER -